SYCE3: A Potential Drug Target and Biomarker forCentral Element Proteins

Target Name: SYCE3

NCBI ID: G644186

SYCE3

SYCE3: A Potential Drug Target and Biomarker forCentral Element Proteins

Abstract:
Central element proteins (CEPs) are a family of proteins that play crucial roles in various cellular processes. SYCE3, a member of the CEP family, has been identified as a potential drug target and biomarker. This article discusses the current understanding of SYCE3, its potential drug implications, and its role as a biomarker for several diseases.

Introduction:
Central element proteins (CEPs) are a family of proteins that have been identified to play a crucial role in various cellular processes. These proteins are involved in various cellular signaling pathways, including DNA replication, gene expression, and cell signaling. One of the well-known CEPs is SYCE3, which is a protein that is involved in the replication of DNA in the nucleus of eukaryotic cells.

SYCE3: A Potential Drug Target:
SYCE3 is a 23-kDa protein that is expressed in various tissues of eukaryotic cells. It is highly conserved and has a similar molecular weight to other CEPs such as DNMT1 and DNMT2. SYCE3 is involved in the replication of DNA in the nucleus of eukaryotic cells, which is a critical process for cell growth, development, and reproduction.

SYCE3 has been identified as a potential drug target due to its unique structure and its involvement in various cellular processes. The structure of SYCE3 is similar to that of other CEPs, with a conserved nucleotide-binding domain and a conserved hypervariable region (HVR). The HVR is involved in the interaction with DNA and other proteins, making it a potential target for small molecules.

SYCE3 has been shown to play a role in various diseases, including cancer, neurodegenerative diseases, and developmental disorders. For example, SYCE3 has been shown to be involved in the development and progression of neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease. Additionally, studies have shown that SYCE3 is involved in the development and progression of cancer, including breast and ovarian cancer.

SYCE3: A Potential Biomarker:
SYCE3 has also been identified as a potential biomarker for several diseases. The replication of DNA in the nucleus of eukaryotic cells is a critical process for cell growth, development, and reproduction, making it an attractive biomarker for various diseases.

Studies have shown that SYCE3 levels are affected by various diseases, including cancer, neurodegenerative diseases, and developmental disorders. For example, higher SYCE3 levels have been shown to be associated with the development and progression of cancer, including breast and ovarian cancer. Additionally, lower SYCE3 levels have been shown to be associated with neurodegenerative diseases, such as Alzheimer's disease and Parkinson's disease.

Conclusion:
In conclusion, SYCE3 is a protein that has been identified as a potential drug target and biomarker for various diseases. Its unique structure and involvement in various cellular processes make it a promising target for small molecules. Further research is needed to fully understand the role of SYCE3 in disease progression and to develop effective treatments.

Protein Name: Synaptonemal Complex Central Element Protein 3

Functions: Major component of the transverse central element of synaptonemal complexes (SCS), formed between homologous chromosomes during meiotic prophase. Required for chromosome loading of the central element-specific SCS proteins, and for initiating synapsis between homologous chromosomes. Chromosome loading appears to require SYCP1. Required for fertility

The "SYCE3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SYCE3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets